Dr John O'Sullivan

MD PhD MSc FAHA FRCPI Cert. Biostatistics (Harvard)Clinical-Academic Cardiologist, Royal Prince Alfred Hospital
Senior Lecturer, Central Clinical School, Sydney Medical School
Group Leader Cardiometabolic Disease, HRI and Charles Perkins Centre

Member of the Charles Perkins Centre


Map

Biographical details

Dr John O’Sullivan is a cardiologist and scientist who studies cardiometabolic disease, particularly the nexus of obesity, diabetes, and cardiovascular disease, now based at the Royal Prince Alfred Hospital, the HRI, and the Charles Perkins Centre. He completed his medical and cardiology training in Ireland, and spent the last 4 years on a postdoctoral fellowship at the Gerszten Lab at Massachusetts General Hospital, Harvard Medical School, and the Broad Institute of Harvard and MIT. There, he performed large scale targeted and non-targeted metabolomics profiling on subjects in the Framingham Heart Study (FHS), validating findings in unrelated cohorts such as the Malmö Diet and Cancer Study (MDC), the Diabetes Prevention Program, and the Jackson Heart Study. This work led to the identification of a number of novel markers and effectors of cardiometabolic disease. Subsequent work demonstrated the ability of intracellular metabolomics profiling to replicate “human disease in a dish” using iPS cells from FHS patients with specific genetic variants. More recently, John performed GWAS on non-targeted metabolomics data to identify an unknown metabolite associated with CT-defined liver fat, subsequently validated this finding in a biopsy-proven cohort, and then demonstrated the ability of this metabolite to predict future diabetes 12 years ahead of presentation in three cohorts of different ethnicity. John’s work has been recognized by a number of Young Investigator Awards at the American College of Cardiology, American Heart Association (AHA) (x2), and Irish Cardiac Society; Fellowship of the AHA; a Harvard Medical School Tosteson Award; the NSW Ministerial Award for Rising Starts in Cardiovascular Research 2016; in addition to other awards at the European Society of Cardiology, Massachusetts General Hospital, and the Irish Cardiac Society. He is keen to expand on this work here in Australia by fostering meaningful and long-lasting collaborations.

Research interests

Our group's interests lie in exploring gene-environment interaction in the development of cardiometabolic disease. In particular, we are interested in understanding how diet, the microbiome, and the metabolome interact to drive cardiovascular diseases like atherosclerosis and heart failure. We have assembled a diverse array of tools to enable us to do so: sophisticated metabolomic and lipidomic platforms; murine models of cardiometabolic disease; stable-isotope labelling flux analysis; clinical research clinics incorporating patient samples and imaging, particularly cardiac MRI; and genotyped induced pluripotent stem cell (iPSC) - cardiomyocyte models. We have extensive access to large-scale human databases that have carefully curated outcome phenotypes (e.g. clinical endpoints such as myocardial infarction) and intermediate phenotypes (e.g. omic data) including the Framingham Heart Study and UK Biobank.
We collaborate closely with investigators at the Charles Perkins Centre with overlapping interests and harness their exerptise to significantly advance our research, e.g. Prof David James leading expertise in metabolism, Prof Stephen Simpson's expertise in dietary models, A/Prof Andrew Holmes expertise in the microbiome.

Current projects

Project 1:

Giving the failing heart the nutrients it needs

The aim of this proposal is to determine the key cardiac substrates depleted in the failing heart, and to determine if replacing them can restore normal heart function. Heart failure (HF) associated with obesity and type 2 diabetes (leading to “stiff hearts”, termed “Heart Failure preserved Ejection Fraction”, or HFpEF), has exploded in prevalence, has no specific treatment, and is driven in large part by altered metabolism. We aim to:

  1. Measure cardiac substrate changes in human HFpEF and determine association with heart function and clinical outcome;
  2. Determine stages of metabolic alteration, and substrate turnover, during the natural history of HFpEF using model systems;
  3. Investigate the effects, and underlying mechanism, of key substrate administration on cardiac function.

Project 2:

Probing microbiome-metabolome-cardiovascular disease interactions

Recent research has shown significant health benefits deriving from high-dietary fiber / microbiome-accessible carbohydrate (MAC) consumption. Compared with native starch, dietary resistant starch is a high-MAC starch that significantly alters the gut microbiome. The aim of our recent study was to determine the systemic metabolic effects of MAC. Male C57BL/6 mice were divided into two groups and fed either native starch or resistant starch for 18 weeks (n = 20/group).Metabolomic analyses revealed plasma levels of numerous metabolites were significantly different between the resistant starch-fed and native starch-fed mice, many of which are microbiome-derived. Most strikingly, we observed a 22-fold increase in gut microbiome-derived tryptophan metabolite indole-3-propionate (IPA), which was positively correlated with several gut microbiota including Clostridiales, Allobaculum, Bifidobacterium, andPrevotella; Allobaculum having the most consistently increased abundance of IPA-associated taxa across all RS-fed mice. In addition, major changes were observed for metabolites solely or primarily metabolized in the gut, e.g., trimethylamine-N-oxide; metabolites that have a significant entero-hepatic circulation, i.e. bile acids; lipid metabolites, e.g. cholesterol sulfate; metabolites indicating increased energy turnover, e.g. tricarboxylic acid cycle (TCA) intermediates and ketone bodies; and increased anti-oxidants such as reduced glutathione. Our findings reveal potentially novel mediators of high MAC-derived health benefits.
We will now extend this analysis and examine the role of IPA, and related indoles, as the major mediators of the cardiometabolic benefits of high-fibre diets. More broadly, we will continue to explore dietary-microbiome-metabolome-CVD interactions.

Awards and honours

Select Awards:

1stPlace, Young Investigator Award, American College of Cardiology (2011).

1stPlace, Young Investigator Award, Irish Cardiac Society (2011).

Young Investigator Award, American Heart Association (Melvin Judkins Award) (2011).

Fellowship of the American Heart Association (FAHA) (2011).

“Top 30 Outstanding Young People in the World” (Medical Innovation), JCI (2011).

Prof Raymond Shanahan Prize in Cardiovascular Research, University College Cork, Cork, Ireland (2011).

Prof Brian McGovern Overseas Training Fellowship to Massachusetts General Hospital; Cardiac Society (2011).

1stPlace Poster, MGH CVRC at the American Academy of Sciences (2014).

Harvard Medical School Tosteson Award for Medical Discovery (2014).

Poster of Distinction Award, 67thAnnual Massachusetts General Hospital Scientific Advisory Committee Meeting (2014).

Young Investigator Award, American Heart Association (AHA) Functional Genomics and Translational Biology (2016).

NSW Ministerial Award for Rising Stars in Cardiovascular Research Excellence (2016).

Sydney Medical School Foundation Chapman Fellowship (2017).

In the media

Publications:

Original Research Articles:

  • Branched chain amino acids impact health and lifespan indirectly via diet balance and appetite control

Samantha M Solon-Biet, Victoria C Cogger, Tamara Pulpitel, Devin Wahl, Ximonie Clark, Alistair Senior, Qiaoping Wang, Amanda Brandon, Ruth Perks, John F. O’Sullivan, Yen C Koay, Kim Bell-Anderson, Melkam Kebede, Belinda Yau, Clare Atkinson, Gunbjorg Svineng, Rosilene Waern, Jibran A Wali, Matthew D Piper, Robert Cumming Vasant Hirani, David J Handelsman, Paula Juricic, Linda Partridge, David Raubenheimer, Gregory Cooney, David G Le Couteur, Stephen J Simpson.

Nature Metabolism, 2019 (accepted).

  • MiRNA93-5p is a Novel Predictor of Coronary Artery Instent Restenosis.

John F. O’Sullivan, Antoinette Neylon, Eoin F. Fahey, Pengyi Yang, Catherine McGorrian, Gavin J. Blake.

Heart Asia, 2019, http://dx.doi.org/10.1136/heartasia-2018-011134

  • Myocardial Metabolic Perturbations in Advanced Ischemic and Non-Ischemic Dilated Human Heart Failure

Jacob Cao, Yen Chin Koay, Lake-Ee Quek, Benjamin Parker, Sean Lal, John F. O’Sullivan.

European Journal of Heart Failure, (accepted 08/04/2019)

  • Ingestion of resistant starch by mice markedly increases microbiome-derived metabolites.

Yen Chin Koay*, Jibran A. Wali*, Alison W. S. Luk, Laurence Macia,Victoria C. Cogger, Tamara J. Pulpitel, Devin Wahl, Samantha M. Solon-Biet, Andrew Holmes,Stephen J. Simpson, John F. O’Sullivan.

FASEB J2019, https://doi.org/10.1096/fj.201900177R.

  • Beta-aminoisobutyric acid as a novel regulator of carbohydrate and lipid metabolism.

Dmitrii A. Tanianskii, Natalia Jarzebska, Andreas L. Birkenfeld, John F. O’Sullivan, and Roman N. Rodionov.

Nutrients, 2019 (accepted 04/2019)

  • DMGV is a marker of liver fat and predicts diabetes.

John F O’Sullivan,Jordan E Morningstar, Baohui Zheng, Sarah Jeanfavre, Justin Scot, Qiong Yang, Celine Fernandez, Ramachandran S. Vasan, Michelle T. Long, Olle Melander, Thomas J. Wang, Caroline Fox, Randall T. Peterson, Clary Clish, Kathleen Corey, Robert E. Gerszten.

J Clin Invest. 2017. PMID: 29083323.

  • Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Stephen T Vernon, Sean Coffey, Ravinay Bhindi, Soon Yeng Soo Hoo, Gregory I Nelson, Michael R Ward, Peter S Hansen, Kaleab N Asrress, Clara K Chow, David Celermajer,John F. O’Sullivan, and Gemma A Figtree.

European Journal of Preventive Cardiology.2017 Jan 1:2047487317720287. PMID:28703626 .

  • Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease.

Curtis R. Warren,John F. O’Sullivan, Max Friesen, Caroline E. Becker, Xiaoling Zhang, Yoshi Wakabayashi, Jordan E. Morningstar,Xu Shi, Jihoon Choi, Fang Xia, Mary H. C. Florido, Jennifer Shay, Derek T. Peters, Kiran Musunuru, Sekar Kathiresan, Laurence Daheron, Jun Zhu, Robert E. Gerszten, Rahul Deo, Vasan Ramachandran, Christopher J. O’Donnell, and Chad A. Cowan.

Cell Stem Cell.2017 Apr 6;20(4):547-557. (Impact Factor 23.6). PMID: 28388431.

  • Metabolomic Profiling Identifies Anandamide as a Biomarker of nonalcoholic steatohepatitis.

William.T. Kimberly,John F O’Sullivan, Anjali Nath, Michelle Keyes, Qiong Yang, Martin G. Larson, Vasan Ramachandran, Randall T. Peterson, Thomas J. Wang, Kathleen Corey, and Robert E. Gerszten.

J Clin Invest. Insight.2017 May 4;2(9). PMID: 28469090.

  • HELZ2 is an IFN Effector Mediating Suppression of Dengue Virus. Dahlene Fusco, Henry Pratt, Wenyu Lin, D. Alex Cronkite, Kate Jeffrey, Joshua Pondick, Alan Mullen, Anthony Anselmo, Ruslan Sadreyev,John O’Sullivan, Robert Gerszten, Tetsurou Satoh, Raymond T. Chung.

Frontiers in Microbiology.Front Microbiol. 2017 Feb 20;8:240. PMID: 28265266.

  • Aptamer-based proteomic profiling reveals novel candidate biomarkers of cardiovascular disease. Debby Ngo, Sumita Sinha, Dongxiao Shen, Eric Kuhn, Michelle Keyes, Xu Shi, Mark Benson,John F O’ Sullivan, HasmikKeshishian, Laurie Farrell, Michael A. Fifer, Ramachandran S. Vasan, Marc Sabatine, Martin G. Larson, Steven A. Carr, Thomas J. Wang, Robert E. Gerszten.

Circulation.2016; 134:270-285. (Impact Factor 14.4). PMID: 27444932.

  • miR-93-5p and other miRNAs as Predictors of Stable Coronary Artery Disease and STEMI.JF O’Sullivan, A Neylon, C McGorrian, G Blake.

International Journal of Cardiology.Dec 2016, Vol 24, 310-316. (Impact Factor 4.0). PMID: 27665403.

  • Integrative analysis of iPS cell models of PRKAG2 cardiomyopathy identifies AMPK as a regulator of cardiomyocyte survival, contractility and fibrosis in microtissues. J. Travis Hinson, Anant Chopra, Calvin C. Sheng, Rajat M. Gupta, Rajarajan Kuppusamy,John F.O’Sullivan, Glenn Rowe, Joshua Gorham, Kiran Musunuru, Robert E. Gerszten, Sean M. Wu, Christopher Chen, Jonathan E. Seidman, Christine E. Seidman.

Cell Reports.2016 Dec 20;17(12):3292-3304.PMID: 28009297. (Impact Factor 7.9).

  • Rapid and efficient generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Christoph Patsch, Ludivine Challet-Meylan, Eva Christina Thoma, Eduard Urich, Tobias Heckel,John F O’Sullivan, Stephanie J Grainger, Friedrich G Karpp, Lin Sun, Klaus Christensen, Yulei Xia, Marie Florido, Wei He, Wei Pan, Michael Prummer, Curtis Warren, Oliver Wernet, Roland Jakob-Roetne, Ulrich Certa, Ravi Jagasia, Per-Ola Freskgård, Isaac Adatto, Dorothee Kling, Paul Huang, Leonard I Zon, Elliot Chaikof, Robert E. Gerzsten, Martin Graf, Roberto Iacone and Chad A. Cowan.

Nature Cell Biology.2015 Aug;17(8):994-1003. (Impact Factor 18.7). PMID: 26214132.

PLoS One.2014 Jun 16;9(6):99058. (Impact Factor 3.2).PMID: 24932507.

  • β-Aminoisobutyric Acid Increases Browning of White Fat and Hepatic β-Oxidation and is Inversely Correlated with Cardiometabolic Risk Factors in Humans. Lee D. Roberts, Pontus Boström,John F. O'Sullivan, Robert T. Schinzel, Gregory D. Lewis, Youn-Kyoung Lee, Melinda J. Palma, Sondra Calhoun, Ming-Huei Chen, Vasan S. Ramachandran, Martin G. Larson, Claude Bouchard, Tuomo Rankinen, Amanda L. Souza, Clary B. Clish, Thomas J. Wang, Alexander A. Soukas, Chad A. Cowan, Bruce M. Spiegelman, Robert E. Gerszten.

Cell Metabolism.Volume 19, Issue 1, 96-108, 7 January 2014. (Impact Factor 17.6).PMID: 24411942.

  • Bone marrow-derived mesenchymal stem cells have innate procoagulant activity and cause microvascular obstruction following intracoronary delivery: amelioration by anti-thrombin therapy. Birgitta M Gleeson,Kenneth Martin, Arun HS Kumar DVM, Mohammed T Ali, M Gopala-Krishnan Pillai,John F O’Sullivan, Derek Whelan, Frank P Barry, Timothy O’Brien, Noel M Caplice.

Stem Cells.2015 Sep;33(9):2726-37.(Impact Factor 7.8). PMID: 25969127.

  • 2-aminoadipic acid is a novel biomarker of diabetes risk and modulates glucose homeostasis. Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, Ghorbani A,O'Sullivan J, Cheng S, Rhee EP, Sinha S, McCabe E, Fox CS, O'Donnell CJ, Ho JE, Florez JC, Magnusson M, Pierce KA, Souza AL, Yu Y, Carter C, Light PE, Melander O, Clish CB, Gerszten RE.

J Clin Invest. 2013 Oct 1;123(10):4309-4317. (Impact Factor 12.6). PMID: 24091325..

  • Multi Detector Computed Tomography Accurately Defines Infarct Size, but not Microvascular Obstruction After Myocardial Infarction (MI).John F O’Sullivan, MD, PhD, Anne-Laure Leblond, PhD, John O’Dea, MD, Ivalina Hristova, BS, Sujith Kumar, DMRIT, Noel M Caplice, MD, PhD.

J Am Coll Cardiol. 2013;61(2):208-210. (Impact Factor 17.8). PMID: 23177294.

  • Association of Bicuspid Aortic Valve with an Abnormally Elongated Rudimentary Chordae Tendinae Protruding into the Left Ventricular Outflow Tract. Abid Hussaini,John F O’Sullivan, Nazima Hussaini, Brendan Meany

Int J Cardiol.01/2012; 159(3):45-6. (Impact Factor 4.0). PMID: 22217483.

  • Potent Long-term Cardioprotective Effects of Single Low Dose Insulin-like Growth Factor-1 (LD-IGF-1) Treatment Post Myocardial Infarction.John F O’Sullivan, Anne-Laure Leblond, Geraldine Kelly, Arun HS Kumar, Pat Metharom, Ivalina Hristova, Niki Alizadeh-Vikali, Brian G Hynes, Rosemary O’Connor, Noel M Caplice.

Circulation: Cardiovascular Interventions2011;4:327-335. (Impact Factor 7.0). PMID: 21712526.

  • Potent EPC conditioned media induced anti-apoptotic, cardiotrophic and proangiogenic effects post myocardial infarction are mediated by IGF-1. Brian Hynes, Arun HS Kumar,John O’Sullivan, Anne-Laure Leblond, Sharon Weiss, Jeffrey Schmeckpeper, Kenneth Martin, Noel M Caplice.

Eur Heart J.2011 Dec 15. (Impact Factor 15.2). PMID: 22173909.

  • Thrombin Stimulates Smooth Muscle Cell Differentiation From Peripheral Blood Mononuclear Cells via Protease-Activated Receptor-1, RhoA, and Myocardin. Kenneth Martin, Sharon Weiss, Pat Metharom, Jeffrey S Schmeckpeper, Brian G Hynes,John F O’Sullivan, Noel M Caplice.

Circulation Research.2009;105:214-218. (Impact Factor 11.0). PMID: 19574550.

  • Enhancing Back-up Support During Difficult Coronary Stent Delivery: Single Center Case Series of Experience with the Heartrail II Catheter. Brian Hynes, Grainne Murphy, James Dollard,John O’Sullivan, Nicholas Ruggerio, Ronan Margey, Thomas J. Kiernan, Eugene McFadden

J Invasive Cardiol.2011;23(3):E43-6. (Impact Factor 1.1).PMID: 21364247.

  • Bone marrow mononuclear stem cells: potential in the treatment of myocardial infarction. Anne-Laure Leblond,John O’Sullivan, Noel Caplice.

Stem Cells and Cloning: Advances and Applications.December 2009, Volume 2009:2 Pages 11 – 19. (Impact Factor 2.7). PMID: 24198506.

  • Ostial left main stenosis in a frequent flyer.O’Sullivan JF, McFadden E

Int J Cardiol.2008 Mar 28.(Impact Factor 4.0). PMID: 18378023.

  • Soft tissue neoplasm invading the heart with associated thrombus in a 74 year old man.John O'Sullivan, David Kerins, Peter McEneaney, Carl Vaughan

Eur J Echocardiogr. 2007 Jul 30. (Impact Factor 4.3).PMID: 17669689.

  • Massive thrombus in the aortic arch: A 59-year-old lady with an unknown familial predisposition to vascular thrombosis.O’Sullivan J, Kerins D, Vaughan C.

Eur J Echocardiogr. 2007 Sep 19. (Impact Factor 4.3). PMID: 17888744.

  • Distinct Effects of High-Glucose Conditions on Endothelial Cells of Macrovascular and Microvascular Origins. A. Duffy, A. Liew,J. O’Sullivan, G. Avalos, A. Samali, T. O’ Brien.

Endothelium.2006 Jan-Feb;13(1):9-16. (Impact Factor 5.5). PMID: 16885062

  • Survival of ruptured abdominal aortic aneurysms in the west of Ireland; do prognostic indicators of outcome exist? Sultan S, Maneshka R,O’ Sullivan J, Hynes N, Quill D, Courtney D.

Vasc Endovasc Surg.2004, Jan-Feb; 38(1):43-9. (Impact Factor 0.9). PMID: 14760476.

  • Aortic Surgery: Do preoperative Cardio-selective β-blockers improve clinical outcome? Sultan S,O’Sullivan J, Manecksha R, Ishak L, Sharman A, Quill D, Courtney D

Irish Journal of Medical Science.01/2002; 171(3):S2:20. (Impact Factor 1.12).

  • Ruptured abdominal aortic aneurysms: prognostic indicators for outcome. Sultan S, Manecksha R,O’Sullivan J, Ishak L, Sharman A, Quill D, Courtney D

Irish Journal of Medical Science.01/2002; 171(3):S2:22. (Impact Factor 1.12).

Reviews:

  • Microribonucleic acids for Prevention of Plaque Rupture and Instent Restenosis: “A Finger in the Dam”.John F O’Sullivan, Kenneth Martin, Noel M Caplice.

State of the Art Paper.J Am Coll Cardiol.2011 Jan 25;57(4):383-9. (Impact Factor 17.8). PMID: 21251577.

  • New Therapeutic Potential of MicroRNA Treatment to Target Vulnerable Atherosclerotic Lesions and Plaque Rupture. Kenneth Martin,John F O’Sullivan, Noel M Caplice.

Current Opinion in Cardiology.2011 Sep 13. (Impact Factor 2.7).PMID: 21918434.

  • MicroRNA Expression in Coronary Artery Disease.John F O’Sullivan, Antoinette Neylon, Catherine McGorrian, Gavin J Blake

MicroRNA.Volume 2, Issue 3, 2013. (Impact Factor 3.8). PMID: 25069444.

Invited Reviews:

  • Metabolite Profiles and the Risk of Cardiometabolic Disease.O’Sullivan J, Gerszten RE

Eur Heart J.2014; 35; 2197–2204. (Impact Factor 15.2). DOI: 10.1093/eurheartj/ehu270.

Research – Book chapters

  • O’Sullivan, J.F., Leblond, A-L, and Caplice, N.M. (2011) Chapter 12 A key role of angiogenesis in recovery from ischaemic heart disease. In M.A. Slevin (ed.)Therapeutic Angiogenesis for Vascular Diseases.Elsevier. pp 267-294. DOI: 10.1007/978-90-481-9495-7_12.

Selected grants

2019

  • Ketone and metabolic profile to understand and optimize the benefit/safety profile of canagliflozin in patients with Type 2 Diabetes and cardiovascular risk; Figtree G, O'Sullivan J; Janssen Research & Development, LLC (USA)/Research Grant.

2017

  • SMS Foundation Grant; O'Sullivan J; Sydney Medical School Foundation/Foundation Grant.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Pinget, G., Tan, J., Janac, B., Kaakoush, N., Angelatos, A., O'Sullivan, J., Koay, Y., Sierro, F., Davis, J., Divakarla, S., Khanal, D., Chrzanowski, W., Macia, L., et al (2019). Impact of the Food Additive Titanium Dioxide (E171) on Gut Microbiota-Host Interaction. Frontiers in Nutrition, 6, 1-13. [More Information]
  • O'Sullivan, J., Neylon, A., Fahey, E., Yang, P., McGorrian, C., Blake, G. (2019). MiR-93-5p is a novel predictor of coronary in-stent restenosis. Heart Asia, , e011134 - 1-e011134 - 4. [More Information]
  • Cartland, S., Genner, S., Martinez, G., Robertson, S., Kockx, M., Lin, R., O'Sullivan, J., Koay, Y., Manuneedhi Cholan, P., Kebede, M., Patel, S., Kavurma, M., et al (2019). TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis. iScience, 12, 41-52. [More Information]
  • Vernon, S., Hansen, T., Kott, K., Yang, J., O'Sullivan, J., Figtree, G. (2019). Utilizing state-of-the-art �omics� technology and bioinformatics to identify new biological mechanisms and biomarkers for coronary artery disease. Microcirculation, 26(2), e12488-9 pages. [More Information]
  • O'Sullivan, J., Morningstar, J., Yang, Q., Zheng, B., Gao, Y., Jeanfavre, S., Scott, J., Fernandez, C., Zheng, H., O'Connor, S., et al (2017). Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. Journal of Clinical Investigation, 127(12), 4394-4402. [More Information]
  • Fusco, D., Pratt, H., Kandilas, S., Cheon, S., Lin, W., Cronkite, D., Basavappa, M., Jeffrey, K., Anselmo, A., O'Sullivan, J., et al (2017). HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus. Frontiers in Microbiology, 8, 1-20. [More Information]
  • Vernon, S., Coffey, S., Bhindi, R., Hoo, S., Nelson, G., Ward, M., Hansen, P., Asrress, K., Chow, C., Celermajer, D., O'Sullivan, J., Figtree, G. (2017). Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. European Journal of Preventive Cardiology, 24(17), 1824-1830. [More Information]
  • Warren, C., O'Sullivan, J., Friesen, M., Becker, C., Zhang, X., Liu, P., Wakabayashi, Y., Morningstar, J., Shi, X., Choi, J., et al (2017). Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease. Cell Stem Cell, 20(4), 547-5.57. [More Information]
  • Kimberly, W., O'Sullivan, J., Nath, A., Keyes, M., Shi, X., Larson, M., Yang, Q., Long, M., Vasana, R., Peterson, R., et al (2017). Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. JCI Insight, 2(9), 1-9. [More Information]
  • Ngo, D., Sinha, S., Shen, D., Kuhn, E., Keyes, M., Shi, X., Benson, M., O'Sullivan, J., Keshishian, H., Farrell, L., et al (2016). Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation, 134(4), 270-285. [More Information]
  • Hinson, J., Chopra, A., Lowe, A., Sheng, C., Gupta, R., Kuppusamy, R., O'Sullivan, J., Rowe, G., Wakimoto, H., et al (2016). Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Reports, 17(12), 3292-3304. [More Information]
  • O'Sullivan, J., Neylon, A., McGorrian, C., Blake, G. (2016). miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. International Journal of Cardiology, 224, 310-316. [More Information]
  • Gleeson, B., Martin, K., Ali, M., Kumar, A., Pillai, M., Kumar, S., O'Sullivan, J., Whelan, D., Stocca, A., et al (2015). Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. Stem Cells, 33(9), 2726-2737. [More Information]
  • Patsch, C., Challet-Meylan, L., Thoma, E., Urich, E., Heckel, T., O'Sullivan, J., Grainger, S., Kapp, F., Sun, L., et al (2015). Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nature Cell Biology, 17(8), 994-1003. [More Information]
  • Roberts, L., Bostrom, P., O'Sullivan, J., Schinzel, R., Lewis, G., Dejam, A., Lee, Y., Palma, M., Calhoun, S., et al (2014). (beta)-Aminoisobutyric acid induces browning of white fat and hepatic (beta)-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metabolism, 19(1), 96-108. [More Information]
  • Turer, A., Lewis, G., O'Sullivan, J., Elmariah, S., Mega, J., Addo, T., Sabatine, M., de Lemos, J., Gerszten, R. (2014). Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. PloS One, 9(6), e99058. [More Information]
  • O'Sullivan, J., Neylon, A., McGorrian, C., Blake, G. (2014). MicroRNA Expression in Coronary Artery Disease. MicroRNA, 2(3), 205-211.
  • Wang, T., Ngo, D., Psychogios, N., Dejam, A., Larson, M., Vasan, R., Ghorbani, A., O'Sullivan, J., Cheng, S., et al (2013). 2-Aminoadipic acid is a biomarker for diabetes risk. Journal of Clinical Investigation, 123(10), 4309-4317. [More Information]
  • O'Sullivan, J., Leblond, A., O'Dea, J., Hristova, I., Kumar, S., Martin, K., Kumar, A., Caplice, N. (2013). Multidetector computed tomography accurately defines infarct size, but not microvascular obstruction after myocardial infarction. Journal of the American College of Cardiology, 61(2), 208-210. [More Information]
  • Hynes, B., Kumar, A., O'Sullivan, J., Klein Buneker, C., Leblond, A., Weiss, S., Schmeckpeper, J., Martin, K., Caplice, N. (2013). Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1. European Heart Journal, 34(10), 782-789. [More Information]
  • Hussaini, A., O'Sullivan, J., Hussain, N., Meany, B. (2012). Association of a bicuspid aortic valve with an abnormally elongated rudimentary chordae tendinae protruding into the left venticular outflow tract. International Journal of Cardiology, 159(3), e45-6. [More Information]
  • Hynes, B., Dollard, J., Murphy, G., O'Sullivan, J., Ruggiero, N., Margey, R., Kiernan, T., McFadden, E. (2011). Enhancing back-up support during difficult coronary stent delivery: single-center case series of experience with the Heartrail II catheter. Journal of Invasive Cardiology, 23(3), E43-E46.
  • O'Sullivan, J., Martin, K., Caplice, N. (2011). Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". Journal of the American College of Cardiology, 57(4), 383-389. [More Information]
  • Martin, K., O'Sullivan, J., Caplice, N. (2011). New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Current Opinion in Cardiology, 26(6), 569-575. [More Information]
  • O'Sullivan, J., Leblond, A., Kelly, G., Kumar, A., Metharom, P., Klein Buneker, C., Alizadeh-Vikali, N., Hristova, I., Hynes, B., O'Connor, R., et al (2011). Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction. Circulation: Cardiovascular Interventions, 4(4), 327-335. [More Information]

2019

  • Pinget, G., Tan, J., Janac, B., Kaakoush, N., Angelatos, A., O'Sullivan, J., Koay, Y., Sierro, F., Davis, J., Divakarla, S., Khanal, D., Chrzanowski, W., Macia, L., et al (2019). Impact of the Food Additive Titanium Dioxide (E171) on Gut Microbiota-Host Interaction. Frontiers in Nutrition, 6, 1-13. [More Information]
  • O'Sullivan, J., Neylon, A., Fahey, E., Yang, P., McGorrian, C., Blake, G. (2019). MiR-93-5p is a novel predictor of coronary in-stent restenosis. Heart Asia, , e011134 - 1-e011134 - 4. [More Information]
  • Cartland, S., Genner, S., Martinez, G., Robertson, S., Kockx, M., Lin, R., O'Sullivan, J., Koay, Y., Manuneedhi Cholan, P., Kebede, M., Patel, S., Kavurma, M., et al (2019). TRAIL-Expressing Monocyte/Macrophages Are Critical for Reducing Inflammation and Atherosclerosis. iScience, 12, 41-52. [More Information]
  • Vernon, S., Hansen, T., Kott, K., Yang, J., O'Sullivan, J., Figtree, G. (2019). Utilizing state-of-the-art �omics� technology and bioinformatics to identify new biological mechanisms and biomarkers for coronary artery disease. Microcirculation, 26(2), e12488-9 pages. [More Information]

2017

  • O'Sullivan, J., Morningstar, J., Yang, Q., Zheng, B., Gao, Y., Jeanfavre, S., Scott, J., Fernandez, C., Zheng, H., O'Connor, S., et al (2017). Dimethylguanidino valeric acid is a marker of liver fat and predicts diabetes. Journal of Clinical Investigation, 127(12), 4394-4402. [More Information]
  • Fusco, D., Pratt, H., Kandilas, S., Cheon, S., Lin, W., Cronkite, D., Basavappa, M., Jeffrey, K., Anselmo, A., O'Sullivan, J., et al (2017). HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus. Frontiers in Microbiology, 8, 1-20. [More Information]
  • Vernon, S., Coffey, S., Bhindi, R., Hoo, S., Nelson, G., Ward, M., Hansen, P., Asrress, K., Chow, C., Celermajer, D., O'Sullivan, J., Figtree, G. (2017). Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. European Journal of Preventive Cardiology, 24(17), 1824-1830. [More Information]
  • Warren, C., O'Sullivan, J., Friesen, M., Becker, C., Zhang, X., Liu, P., Wakabayashi, Y., Morningstar, J., Shi, X., Choi, J., et al (2017). Induced Pluripotent Stem Cell Differentiation Enables Functional Validation of GWAS Variants in Metabolic Disease. Cell Stem Cell, 20(4), 547-5.57. [More Information]
  • Kimberly, W., O'Sullivan, J., Nath, A., Keyes, M., Shi, X., Larson, M., Yang, Q., Long, M., Vasana, R., Peterson, R., et al (2017). Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis. JCI Insight, 2(9), 1-9. [More Information]

2016

  • Ngo, D., Sinha, S., Shen, D., Kuhn, E., Keyes, M., Shi, X., Benson, M., O'Sullivan, J., Keshishian, H., Farrell, L., et al (2016). Aptamer-Based Proteomic Profiling Reveals Novel Candidate Biomarkers and Pathways in Cardiovascular Disease. Circulation, 134(4), 270-285. [More Information]
  • Hinson, J., Chopra, A., Lowe, A., Sheng, C., Gupta, R., Kuppusamy, R., O'Sullivan, J., Rowe, G., Wakimoto, H., et al (2016). Integrative Analysis of PRKAG2 Cardiomyopathy iPS and Microtissue Models Identifies AMPK as a Regulator of Metabolism, Survival, and Fibrosis. Cell Reports, 17(12), 3292-3304. [More Information]
  • O'Sullivan, J., Neylon, A., McGorrian, C., Blake, G. (2016). miRNA-93-5p and other miRNAs as predictors of coronary artery disease and STEMI. International Journal of Cardiology, 224, 310-316. [More Information]

2015

  • Gleeson, B., Martin, K., Ali, M., Kumar, A., Pillai, M., Kumar, S., O'Sullivan, J., Whelan, D., Stocca, A., et al (2015). Bone Marrow-Derived Mesenchymal Stem Cells Have Innate Procoagulant Activity and Cause Microvascular Obstruction Following Intracoronary Delivery: Amelioration by Antithrombin Therapy. Stem Cells, 33(9), 2726-2737. [More Information]
  • Patsch, C., Challet-Meylan, L., Thoma, E., Urich, E., Heckel, T., O'Sullivan, J., Grainger, S., Kapp, F., Sun, L., et al (2015). Generation of vascular endothelial and smooth muscle cells from human pluripotent stem cells. Nature Cell Biology, 17(8), 994-1003. [More Information]

2014

  • Roberts, L., Bostrom, P., O'Sullivan, J., Schinzel, R., Lewis, G., Dejam, A., Lee, Y., Palma, M., Calhoun, S., et al (2014). (beta)-Aminoisobutyric acid induces browning of white fat and hepatic (beta)-oxidation and is inversely correlated with cardiometabolic risk factors. Cell Metabolism, 19(1), 96-108. [More Information]
  • Turer, A., Lewis, G., O'Sullivan, J., Elmariah, S., Mega, J., Addo, T., Sabatine, M., de Lemos, J., Gerszten, R. (2014). Increases in myocardial workload induced by rapid atrial pacing trigger alterations in global metabolism. PloS One, 9(6), e99058. [More Information]
  • O'Sullivan, J., Neylon, A., McGorrian, C., Blake, G. (2014). MicroRNA Expression in Coronary Artery Disease. MicroRNA, 2(3), 205-211.

2013

  • Wang, T., Ngo, D., Psychogios, N., Dejam, A., Larson, M., Vasan, R., Ghorbani, A., O'Sullivan, J., Cheng, S., et al (2013). 2-Aminoadipic acid is a biomarker for diabetes risk. Journal of Clinical Investigation, 123(10), 4309-4317. [More Information]
  • O'Sullivan, J., Leblond, A., O'Dea, J., Hristova, I., Kumar, S., Martin, K., Kumar, A., Caplice, N. (2013). Multidetector computed tomography accurately defines infarct size, but not microvascular obstruction after myocardial infarction. Journal of the American College of Cardiology, 61(2), 208-210. [More Information]
  • Hynes, B., Kumar, A., O'Sullivan, J., Klein Buneker, C., Leblond, A., Weiss, S., Schmeckpeper, J., Martin, K., Caplice, N. (2013). Potent endothelial progenitor cell-conditioned media-related anti-apoptotic, cardiotrophic, and pro-angiogenic effects post-myocardial infarction are mediated by insulin-like growth factor-1. European Heart Journal, 34(10), 782-789. [More Information]

2012

  • Hussaini, A., O'Sullivan, J., Hussain, N., Meany, B. (2012). Association of a bicuspid aortic valve with an abnormally elongated rudimentary chordae tendinae protruding into the left venticular outflow tract. International Journal of Cardiology, 159(3), e45-6. [More Information]

2011

  • Hynes, B., Dollard, J., Murphy, G., O'Sullivan, J., Ruggiero, N., Margey, R., Kiernan, T., McFadden, E. (2011). Enhancing back-up support during difficult coronary stent delivery: single-center case series of experience with the Heartrail II catheter. Journal of Invasive Cardiology, 23(3), E43-E46.
  • O'Sullivan, J., Martin, K., Caplice, N. (2011). Microribonucleic acids for prevention of plaque rupture and in-stent restenosis: "a finger in the dam". Journal of the American College of Cardiology, 57(4), 383-389. [More Information]
  • Martin, K., O'Sullivan, J., Caplice, N. (2011). New therapeutic potential of microRNA treatment to target vulnerable atherosclerotic lesions and plaque rupture. Current Opinion in Cardiology, 26(6), 569-575. [More Information]
  • O'Sullivan, J., Leblond, A., Kelly, G., Kumar, A., Metharom, P., Klein Buneker, C., Alizadeh-Vikali, N., Hristova, I., Hynes, B., O'Connor, R., et al (2011). Potent long-term cardioprotective effects of single low-dose insulin-like growth factor-1 treatment postmyocardial infarction. Circulation: Cardiovascular Interventions, 4(4), 327-335. [More Information]

To update your profile click here. For support on your academic profile contact .